ID   PCI-38
AC   CVCL_M471
SY   PCI38
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 988
DR   Cell_Model_Passport; SIDM00155
DR   Cosmic-CLP; 1240205
DR   DepMap; ACH-002296
DR   EGA; EGAS00001000978
DR   GDSC; 1240205
DR   GEO; GSM1670343
DR   PharmacoDB; PCI38_1252_2019
DR   Wikidata; Q54938698
RX   PubMed=8084624;
RX   PubMed=17312569;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=3.33%; Native American=0%; East Asian, North=3.92%; East Asian, South=0%; South Asian=6.82%; European, North=30.5%; European, South=55.42% (PubMed=30894373).
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 13
ST   D5S818: 11
ST   D7S820: 9,10
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 30-01-24; Version: 19
//
RX   PubMed=8084624; DOI=10.1177/01945998941113P105;
RA   Snyderman C.H., Klapan I., Milanovich M., Heo D.S., Wagner R.,
RA   Schwartz D.R., Johnson J.T., Whiteside T.L.;
RT   "Comparison of in vivo and in vitro prostaglandin E2 production by
RT   squamous cell carcinoma of the head and neck.";
RL   Otolaryngol. Head Neck Surg. 111:189-196(1994).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//